Cargando…
A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump
BACKGROUND: Convenient dosing is a key component of treatment adherence and thus efficacy and safety. Aqueous sublingual immunotherapy (SLIT) formulations can be administered with a dosing pump that delivers 200 µL of volume per actuation. OBJECTIVE: The objective of this study was to describe the u...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128946/ https://www.ncbi.nlm.nih.gov/pubmed/33591547 http://dx.doi.org/10.1007/s40801-021-00233-y |
_version_ | 1783694204523773952 |
---|---|
author | Roger Reig, Albert Padró Casas, Clara Gutiérrez Fernández, Diego Orta Cuevas, José Carlos Sánchez López, Germán Corzo Higueras, José Luis |
author_facet | Roger Reig, Albert Padró Casas, Clara Gutiérrez Fernández, Diego Orta Cuevas, José Carlos Sánchez López, Germán Corzo Higueras, José Luis |
author_sort | Roger Reig, Albert |
collection | PubMed |
description | BACKGROUND: Convenient dosing is a key component of treatment adherence and thus efficacy and safety. Aqueous sublingual immunotherapy (SLIT) formulations can be administered with a dosing pump that delivers 200 µL of volume per actuation. OBJECTIVE: The objective of this study was to describe the use of Staloral(®) 300 Rapid in its new dosing pump presentation and to evaluate the safety and satisfaction from both the patient and doctor. PATIENTS AND METHODS: We performed a retrospective non-interventional study in a population (aged 5 years or over) of individuals with allergic rhinitis or allergic asthma who were being treated with aqueous 300 index of reactivity SLIT formulations of various allergens (grass pollen, tree pollen, house dust mites). Based on a detailed, SLIT-specific, patient self-questionnaire (Quartis(®)) and the inspection of medical records, we assessed the characteristics of the SLIT, safety, patient satisfaction and willingness to continue SLIT. The physician’s satisfaction with the treatment was measured on a 0–100 visual analogue scale. Adverse events were coded with the Medical Dictionary for Regulatory Activities. RESULTS: A total of 801 valid patients were included (52.4% male; mean ± standard deviation age: 25.9 ± 17.2 years; mean time since diagnosis: 4.56 ± 4.68 years; mean time using the previous dosing pump: 19.2 ± 13.0 months; time using the 200-µL dosing pump: 14.95 ± 3.80 months). Among the study population, 317 subjects comprised the paediatric subgroup (57%: male; mean age: 9.8 ± 2.5 years). Overall, 54 patients (6.7%) reported a total of 68 adverse events (including 51 gastrointestinal adverse events). The large majority of adverse events were mild, local and transient and did not require treatment. There were no severe adverse events. The level of patient satisfaction with the ease of SLIT administration was high (84.3% overall, and 82.6% in the paediatric subgroup). The mean ± standard deviation visual analogue scale score for physician satisfaction with the treatment was 70.6 ± 25.1 out of 100. CONCLUSIONS: Administration of 300 index of reactivity SLIT with a 200-µL dosing pump is safe, well tolerated and associated with good levels of patient satisfaction. |
format | Online Article Text |
id | pubmed-8128946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-81289462021-05-27 A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump Roger Reig, Albert Padró Casas, Clara Gutiérrez Fernández, Diego Orta Cuevas, José Carlos Sánchez López, Germán Corzo Higueras, José Luis Drugs Real World Outcomes Original Research Article BACKGROUND: Convenient dosing is a key component of treatment adherence and thus efficacy and safety. Aqueous sublingual immunotherapy (SLIT) formulations can be administered with a dosing pump that delivers 200 µL of volume per actuation. OBJECTIVE: The objective of this study was to describe the use of Staloral(®) 300 Rapid in its new dosing pump presentation and to evaluate the safety and satisfaction from both the patient and doctor. PATIENTS AND METHODS: We performed a retrospective non-interventional study in a population (aged 5 years or over) of individuals with allergic rhinitis or allergic asthma who were being treated with aqueous 300 index of reactivity SLIT formulations of various allergens (grass pollen, tree pollen, house dust mites). Based on a detailed, SLIT-specific, patient self-questionnaire (Quartis(®)) and the inspection of medical records, we assessed the characteristics of the SLIT, safety, patient satisfaction and willingness to continue SLIT. The physician’s satisfaction with the treatment was measured on a 0–100 visual analogue scale. Adverse events were coded with the Medical Dictionary for Regulatory Activities. RESULTS: A total of 801 valid patients were included (52.4% male; mean ± standard deviation age: 25.9 ± 17.2 years; mean time since diagnosis: 4.56 ± 4.68 years; mean time using the previous dosing pump: 19.2 ± 13.0 months; time using the 200-µL dosing pump: 14.95 ± 3.80 months). Among the study population, 317 subjects comprised the paediatric subgroup (57%: male; mean age: 9.8 ± 2.5 years). Overall, 54 patients (6.7%) reported a total of 68 adverse events (including 51 gastrointestinal adverse events). The large majority of adverse events were mild, local and transient and did not require treatment. There were no severe adverse events. The level of patient satisfaction with the ease of SLIT administration was high (84.3% overall, and 82.6% in the paediatric subgroup). The mean ± standard deviation visual analogue scale score for physician satisfaction with the treatment was 70.6 ± 25.1 out of 100. CONCLUSIONS: Administration of 300 index of reactivity SLIT with a 200-µL dosing pump is safe, well tolerated and associated with good levels of patient satisfaction. Springer International Publishing 2021-02-16 /pmc/articles/PMC8128946/ /pubmed/33591547 http://dx.doi.org/10.1007/s40801-021-00233-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Article Roger Reig, Albert Padró Casas, Clara Gutiérrez Fernández, Diego Orta Cuevas, José Carlos Sánchez López, Germán Corzo Higueras, José Luis A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title | A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title_full | A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title_fullStr | A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title_full_unstemmed | A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title_short | A Retrospective Nationwide Non-Interventional Study of an Aqueous Sublingual Immunotherapy Formulation Administered with a 200-µL Dosing Pump |
title_sort | retrospective nationwide non-interventional study of an aqueous sublingual immunotherapy formulation administered with a 200-µl dosing pump |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128946/ https://www.ncbi.nlm.nih.gov/pubmed/33591547 http://dx.doi.org/10.1007/s40801-021-00233-y |
work_keys_str_mv | AT rogerreigalbert aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT padrocasasclara aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT gutierrezfernandezdiego aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT ortacuevasjosecarlos aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT sanchezlopezgerman aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT corzohiguerasjoseluis aretrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT rogerreigalbert retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT padrocasasclara retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT gutierrezfernandezdiego retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT ortacuevasjosecarlos retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT sanchezlopezgerman retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump AT corzohiguerasjoseluis retrospectivenationwidenoninterventionalstudyofanaqueoussublingualimmunotherapyformulationadministeredwitha200μldosingpump |